The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparative efficacy of everolimus versus fulvestrant for hormone-receptor–positive (HR+) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis.
Thomas Denis Bachelot
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Maria Cikalo
Research Funding - Novartis
Rachael McCool
Research Funding - Novartis
Sarah King
Research Funding - Novartis
Steven Duffy
Research Funding - Novartis
Julie Glanville
Research Funding - Novartis
Danielle Varley
Research Funding - Novartis
Jie Zhang
Employment or Leadership Position - Novartis